Healing of subtrochanteric atypical fractures after strontium ranelate treatment

Clinical Cases in Mineral and Bone Metabolism

Volumn 9, Issue 3, 2012, Pages 166-169

  Negri, Armando Luis ^a   Spivacow, Francisco Rodolfo ^a  

^a UNIVERSIDAD DEL SALVADOR   (Argentina)

Author keywords

Atypical fractures; Bisphosphonate; Delayed healing; Strontium ranelate

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; CALCIUM SALT; ESTROGEN; IBANDRONIC ACID; OSTEOCALCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHORUS; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE RADIOGRAPHY; CALCIUM BLOOD LEVEL; CASE REPORT; CORTICAL BONE; DRUG WITHDRAWAL; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE HEALING; HUMAN; INTRAMEDULLARY NAILING; LEG PAIN; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; SUBTROCHANTERIC ATYPICAL FRACTURE; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

EID: 84871880291     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, NevittMC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541. (Pubitemid 26411651)
2. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 2000;11(1):83-91. (Pubitemid 30099515)
3. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-2294.
4. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-350. (Pubitemid 351630250)
5. Lenart BA, Lorich DG, Lane JM Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-1306. (Pubitemid 351439247)
6. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009;85:37-44.
7. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20:1353-1362.
8. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761-1771.
9. Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. Clin Endocrinol Metab 2011;96(6):1627-32.
10. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical Femoral Fractures during Prolonged Use of Bisphosphonates: Short-Term Responses to Strontium Ranelate and Teriparatide. J Clin Endocrinol Metab 2011 Jul.
11. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-1565.
12. Odvina CV, Zerwekh JE, Rao DE, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301. (Pubitemid 40463979)
13. Charopoulos I, Orme S, Giannoudis PV. Fracture risk associated with chronic use of bisphosphonates: evidence today. Expert Opin Drug Saf 2011;10(1):67-76.
14. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349-353. (Pubitemid 46563912)
15. Kwek EB, Goh SK, Koh JS, PNG MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long term complication of alendronate therapy? Injury 2008;39:224-231.
16. Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22(2):373-390.
17. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24(6):1095-1102.
18. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunrai N, Austin PC, Whelan DB, Weiler PJ, Laupacis A. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305(8):783-789.
19. Capeci CM, Tejwani NC Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009;91:2556-2561.
20. Das De S, Setiobudi T, Shen L. A rational approach to management of alendronate-related subtrochanteric fractures.J Bone Joint Surg Br 2010;92:679-686.
21. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-129. (Pubitemid 32912229)
22. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468. (Pubitemid 38133766)
23. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-2822. (Pubitemid 40686329)
24. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-2066. (Pubitemid 34521489)
25. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, Allain P, Tsouderos Y, Meunier PJ. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996;11(9):1302-11. (Pubitemid 26282531)
26. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP, Delmas PD, Meunier PJ. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008;23(2):215-22. (Pubitemid 351160035)
27. Li Y, Feng G, Gao Y, Luo E, Liu X, Hu J. Strontium ranelate treatment enhances hydroxyapatite-coated titanium screws fixation in osteoporotic rats. J Orthop Res 2009;28:578-582.
28. Li YF, Luo E, Feng G, Zhu SS, Li JH, Hu J. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int 2010;21(11):1889-97.